Company announces positive results from Phase 3 DESTINY-Breast04 Trial of trastuzumab deruxtecan (Enhertu) in patients with HER2 low metastatic breast cancer

Company reported a statistically significant and clinically meaningful improvement in both progression-free- and overall survival in patients with HER2 low unresectable and/or metastatic breast cancer regardless of hormone receptor status versus physician’s choice of chemotherapy

SPS commentary:

Trastuzumab consists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker.  In the UK it is licenced for unresectable/metastatic HER2+ve breast cancer in those who have had 2 or more prior anti-HER2-based regimens.

Biospace Inc.